FBXO4 loss facilitates carcinogen induced papilloma development in mice.

abstract：:We developed a DNA aptamer, Ap52, against the shared tumor-specific MAGE-A3111-125 peptide antigen that was used to target multiple types of cancer cells. Here we report the in vivo study of mice implanted with pancreatic tumor cells AsPC-1, which demonstrates accumulation of phosphorothioate-modified Ap52 (ThioAp52) ...

journal_title：Cancer biology & therapy

authors： Wang CY,Lin BL,Chen CH

更新日期：2021-01-02 00:00:00

abstract：:Antitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial growth factor (VEGF), and angiogenesis. In a cell-free system, C...

journal_title：Cancer biology & therapy

authors： Paradziej-Łukowicz J,Skwarska A,Peszyńska-Sularz G,Brillowska-Dąbrowska A,Konopa J

更新日期：2011-10-01 00:00:00

abstract：:Understanding molecular mechanisms involved in melanoma resistance to drugs is a big challenge. Experimental evidences suggested a correlation between mutational status in B-RAF and melanoma cell susceptibility to drugs, such as paclitaxel, doxorubicin and temozolomide, which generate an accumulation of hydrogen perox...

journal_title：Cancer biology & therapy

authors： Fico A,Alfano D,Valentino A,Vasta V,Cavalcanti E,Travali S,Patriarca EJ,Caputo E

更新日期：2015-01-01 00:00:00

abstract：:AMPK has been termed the fuel sensor of mammalian cells because it directly responds to the depletion of the fuel molecule ATP. In previous work, we found that AMPK is strongly activated by tumor-like hypoxia and glucose deprivation, independently of the oxygen response system associated with HIF-1. We also observed h...

journal_title：Cancer biology & therapy

authors： Laderoute KR,Calaoagan JM,Madrid PB,Klon AE,Ehrlich PJ

更新日期：2010-07-01 00:00:00

abstract：:Arsenic trioxide (As2O3) induces apoptosis in certain types of cancer cells. But the detailed mechanisms of As2O3 efficacy are not completely known. Here we demonstrate that As2O3 has a therapeutic effect on cervical cancer in vitro and in vivo. We investigated the As2O3-induced apoptosis in various cervical cancer ce...

journal_title：Cancer biology & therapy

authors： Yu J,Qian H,Li Y,Wang Y,Zhang X,Liang X,Fu M,Lin C

更新日期：2007-04-01 00:00:00

abstract：:The objective of the present study was to evaluate CA19-9 and CK8/18 expression patterns in pancreatic cancer cell lines induced by 5-fluorouracil (5-Fu), and in circulating tumor cells (CTCs) in peripheral blood of patients previously untreated with advanced pancreatic cancer. Furthermore, the goal was to test the re...

journal_title：Cancer biology & therapy

authors： Ren C,Han C,Zhang J,He P,Wang D,Wang B,Zhao P,Zhao X

更新日期：2011-10-15 00:00:00

abstract：:The molecular phenotype of tumor vasculature is different from normal vasculature, offering new opportunities for diagnosis and therapy of cancer, but the identification of tumor-restricted targets remains a challenge. We investigated 13 tumor vascular markers (TVMs) from 50 candidates identified through expression pr...

journal_title：Cancer biology & therapy

authors： Sasaroli D,Gimotty PA,Pathak HB,Hammond R,Kougioumtzidou E,Katsaros D,Buckanovich R,Devarajan K,Sandaltzopoulos R,Godwin AK,Scholler N,Coukos G

更新日期：2011-08-01 00:00:00

abstract：:The present studies sought to further understand how the anti-folate pemetrexed and the multi-kinase inhibitor sorafenib interact to kill tumor cells. Sorafenib activated SRC, and via SRC the drug combination activated ERK1/2. Expression of dominant negative SRC or dominant negative MEK1 abolished drug-induced ERK1/2 ...

journal_title：Cancer biology & therapy

authors： Bareford MD,Hamed HA,Allegood J,Cruickshanks N,Poklepovic A,Park MA,Ogretmen B,Spiegel S,Grant S,Dent P

更新日期：2012-07-01 00:00:00

abstract：:The surprising results published by FIRE-3 revealed that the overall survival (OS) of RAS wild-type metastatic colorectal cancer (mCRC) patients treated with Cetuximab(Cmab) and FOLFIRI combination was prolonged to 33.1 months. The substantial increase in testing and treatment costs, however, impose a considerable hea...

journal_title：Cancer biology & therapy

authors： Wen F,Yang Y,Zhang P,Zhang J,Zhou J,Tang R,Chen H,Zheng H,Fu P,Li Q

更新日期：2015-01-01 00:00:00

abstract：:The role of immunotherapy in combination with traditional treatment regime in improving the survival of cancer patients has attracted more and more attention. Especially the abscopal effect that describes the phenomenon of localized radiotherapy leading to regression of distant unirradiated tumors and the role of enha...

journal_title：Cancer biology & therapy

authors： Shi F,Wang X,Teng F,Kong L,Yu J

更新日期：2017-03-04 00:00:00

abstract：:Oral squamous cell carcinoma (OSCC), the subtype of head and neck cancers, is notorious for its high incidence and death rate. The role of long non-coding RNAs (lncRNAs) is discovered to be significant for the canceration and cancer progression. Long intergenic non-protein coding RNA 958 (LINC00958) is discovered as a...

journal_title：Cancer biology & therapy

authors： Chen F,Liu M,Yu Y,Sun Y,Li J,Hu W,Wang X,Tong D

更新日期：2019-01-01 00:00:00

abstract：:We investigated the cytotoxic interactions of romidepsin, a histone deacetylase inhibitor, and lenalidomide, an immunomodulatory agent, in a T-cell lymphoma preclinical model. Hut-78 and Karpas-299 cells were treated with romidepsin and lenalidomide alone and in combination. The interaction between romidepsin and lena...

journal_title：Cancer biology & therapy

authors： Cosenza M,Civallero M,Fiorcari S,Pozzi S,Marcheselli L,Bari A,Ferri P,Sacchi S

更新日期：2016-10-02 00:00:00

abstract：:Male germ cell tumors (GCTs) are a model for a curable solid tumor. GCTs can differentiate into mature teratomas. Embryonal carcinomas (ECs) represent the stem cell compartment of GCTs and are the malignant counterpart to embryonic stem (ES) cells. GCTs and EC cells are useful to investigate differentiation therapy an...

journal_title：Cancer biology & therapy

authors： Busch AM,Galimberti F,Nehls KE,Roengvoraphoj M,Sekula D,Li B,Guo Y,Direnzo J,Fiering SN,Spinella MJ,Robbins DJ,Memoli VA,Freemantle SJ,Dmitrovsky E

更新日期：2014-04-01 00:00:00

abstract：:Resistance to apoptosis is one reason for the poor response of malignant brain tumors to therapy. The PPARgamma-modulating drug Troglitazone downregulates the anti-apoptotic FLIP protein and sensitizes glioblastoma cells to apoptosis induced by the death ligand TRAIL. To investigate the molecular basis of an experimen...

journal_title：Cancer biology & therapy

authors： Grund K,Ahmadi R,Jung F,Funke V,Gdynia G,Benner A,Sykora J,Walczak H,Joos S,Felsberg J,Reifenberger G,Wiestler OD,Herold-Mende C,Roth W

更新日期：2008-12-01 00:00:00

abstract：:We have previously identified tumor susceptibility gene101 (TSG101), overexpressed in vincristine-resistant human gastric adenocarcinoma cell line SGC7901/VCR using a modified subtractive hybridization method and Western blot. In the present study, we constructed two siRNA eukaryotic expression vectors of TSG101 and t...

journal_title：Cancer biology & therapy

authors： Shen H,Pan Y,Han Z,Hong L,Liu N,Han S,Yao L,Xie H,Zhaxi C,Shi Y,Fan D

更新日期：2004-06-01 00:00:00

abstract：:DNA methylation at the 5 position of cytosine (5-mC) has emerged as a key epigenetic marker that plays essential roles in various biological and pathological processes. 5-mC can be converted to 5-hydroxymethylcytosine (5-hmC) by the ten-eleven translocation (TET) family proteins, which is now widely recognized as the ...

journal_title：Cancer biology & therapy

authors： Ye C,Li L

更新日期：2014-01-01 00:00:00

abstract：PURPOSE:Induction chemotherapy has shown to provide consistent benefit for local control in primary treatment of advanced oropharyngeal cancer. The beneficial role of chemoradiation following induction chemotherapy over concurrent chemoradiation has not been evaluated. Present study evaluates the same prospectively. R...

journal_title：Cancer biology & therapy

authors： Gupta D,Shukla P,Bisht SS,Dhawan A,Pant MC,Bhatt ML,Gupta S,Gupta R,Negi MP

更新日期：2009-02-01 00:00:00

abstract：:A greater understanding of the molecular basis of breast cancer metastasis will lead to identification of novel therapeutic targets and better treatments. Rap1B is a small GTPase that suppresses the metastasis of breast cancer cells by increasing cell-cell adhesion. In breast cancer, a decrease in Rap1B prenylation an...

journal_title：Cancer biology & therapy

authors： Wilson JM,Lorimer E,Tyburski MD,Williams CL

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Mutations that activate the PI3K/AKT/mTOR pathway are relatively common in urothelial (bladder) cancers, but how these pathway mutations affect AKT dependency is not known. We characterized the relationship between AKT pathway mutational status and sensitivity to the effects of the selective AKT kinase inhib...

journal_title：Cancer biology & therapy

authors： Dickstein RJ,Nitti G,Dinney CP,Davies BR,Kamat AM,McConkey DJ

更新日期：2012-11-01 00:00:00

abstract：:The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free survival (PFS), objecti...

journal_title：Cancer biology & therapy

authors： Chau V,Madan RA,Figg WD

更新日期：2020-10-02 00:00:00

abstract：:Camptothecins are commonly used chemotherapeutics; in some models, they enhance signaling via the mitogen-activated protein kinase (MAPK) pathway through effects on upstream kinases. To evaluate the impact of camptothecin (CPT) on MAPKs in human colon cancer, we studied HCT116 and CaCo2 colon cancer cells. We found th...

journal_title：Cancer biology & therapy

authors： Lee M,Young Kim S,Kim J,Kim HS,Kim SM,Kim EJ

更新日期：2013-11-01 00:00:00

abstract：PURPOSE:Fibroblast Activation Protein (FAP) is a tumor fibroblast protease that has been shown to potentiate colorectal cancer growth. The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic ...

journal_title：Cancer biology & therapy

authors： Narra K,Mullins SR,Lee HO,Strzemkowski-Brun B,Magalong K,Christiansen VJ,McKee PA,Egleston B,Cohen SJ,Weiner LM,Meropol NJ,Cheng JD

更新日期：2007-11-01 00:00:00

abstract：:Tumors with identical phenotype can have markedly different biologic behavior. The differentiation between hemangioblastoma, a benign vascular brain tumor, and renal cell carcinoma (RCC), a malignant tumor that can metastasize to the brain, is a well-known pathological quandary. We report a 59-year-old female with von...

journal_title：Cancer biology & therapy

authors： Gläsker S,Lonser RR,Okamoto H,Li J,Jaffee H,Oldfield EH,Zhuang Z,Vortmeyer AO

更新日期：2007-03-01 00:00:00

abstract：:KLF4 is induced upon growth-arrest in vitro and during epithelial maturation in vivo, and is essential for proper cell fate specification of post-mitotic cells. In spite of a normal role in post-mitotic cells, expression is upregulated and constitutive in certain tumor types. KLF4 functions as an oncogene in vitro, an...

journal_title：Cancer biology & therapy

authors： Huang CC,Liu Z,Li X,Bailey SK,Nail CD,Foster KW,Frost AR,Ruppert JM,Lobo-Ruppert SM

更新日期：2005-12-01 00:00:00

abstract：:Obesity is considered one of the risk factors for many cancers. Serum leptin levels are often elevated in obese people. Leptin has been reported to act as a mitogenic agent and promote renal cancer cell proliferation, whereas the detailed mechanisms still remain to be elucidated. The purpose of this study is to invest...

journal_title：Cancer biology & therapy

authors： Li L,Gao Y,Zhang LL,He DL

更新日期：2008-11-01 00:00:00

abstract：:Tumor growth is often associated with insufficient apoptosis. The Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) and its proapoptotic receptors death receptor 4 (DR4) and DR5 agonistic monoclonal antibodies are being developed as targeted therapeutics because they kill cancer cells while sparing...

journal_title：Cancer biology & therapy

authors： Zhou L,Wang W,Dicker DT,Humphreys RC,El-Deiry WS

更新日期：2011-08-15 00:00:00

abstract：:Tumor formation in immunocompetent hosts is believed to be dependent on the ability of tumor cells to evade the immune system, as suggested by the alterations of expression of the major histocompatibility complex (MHC) and related molecules in a number of cancers. Our previous serial analysis of gene expression (SAGE)...

journal_title：Cancer biology & therapy

authors： Rangel LB,Agarwal R,Sherman-Baust CA,Mello-Coelho Vd,Pizer ES,Ji H,Taub DD,Morin PJ

更新日期：2004-10-01 00:00:00

abstract：:We investigated whether expression of the IL-12 p35 subunit in membrane-bound form in tumor cells enhanced their immunogenicity. Since p35 is only secreted when associated with the IL-12 p40 subunit, we generated tumor cells expressing membrane-bound forms of p35 and p40 as chimeras with the transmembrane/cytoplasmic ...

journal_title：Cancer biology & therapy

authors： Lim HY,Ju HY,Chung HY,Kim YS

更新日期：2010-08-15 00:00:00

abstract：:Current treatment modalities for pancreatic carcinoma afford only modest survival benefits. TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new treatment option. However, since not all pancreatic cancer cells respond to TRAIL, further improvements and optimizations are still ...

journal_title：Cancer biology & therapy

authors： Yu R,Albarenque SM,Cool RH,Quax WJ,Mohr A,Zwacka RM

更新日期：2014-01-01 00:00:00

abstract：:Mutationally activated and oncogenic versions of the ras genes were first identified in human tumors in 1982. This discovery prompted great interest in the development of anti-Ras strategies as novel, target-based approaches for cancer treatment. The three human ras genes represent the most frequently mutated oncogene...

journal_title：Cancer biology & therapy

authors： Cox AD,Der CJ

更新日期：2002-11-01 00:00:00